Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02299999
Other study ID # UC-0105/1304
Secondary ID 2013-001652-36
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date April 7, 2014
Est. completion date December 2024

Study information

Verified date January 2024
Source UNICANCER
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Open label multicentric phase II randomized trial, using high throughput genome analysis as a therapeutic decision tool, which aims at comparing a targeted treatment administered according to the identified molecular anomalies of the tumor with maintenance chemotherapy (targeted substudy 1) as well as immunotherapy with maintenance chemotherapy in patients without actionable genomic alterations or non eligible to substudy 1 (immune substudy 2).


Description:

Screening phase: New frozen biopsy or an archived frozen sample or ctDNA sample will be sent to the genomic platforms for DNA extraction and genomic analysis (DNA microarrays and Next generation sequencing). Patients can be considered as pre-eligible for the targeted substudy 1 randomisation phase when both following mandatory conditions have been met: stable or responding disease has been observed (investigator judgment) after 6 to 8 cycles of chemotherapy (or at least after 4 cycles of chemotherapy if stopped for toxicity) and targetable alteration has been identified by the Molecular Tumor Board (MTB). If not eligible for the substudy 1 randomisation phase, patients can be considered as pre-eligible for the immune substudy 2 randomization phase when both following mandatory conditions are met: stable or responding disease (investigator judgment) is observed after 6 to 8 cycles of chemotherapy (or at least after 4 cycles if treatment was stopped due to toxicity) AND not eligible to randomization in the substudy 1 (because patient had no targetable alteration identified by the Molecular Tumor Board, or failed to have a genomic profile for the tumor [low tumor cells percentage, technical issue during genomic analysis, etc.], or a non inclusion criteria that precluded entry into the substudy 1) Randomization phase: The mandatory post-chemotherapy wash-out period, of 28 days for 21 or 28 day-cycle chemotherapies or of 15 days for weekly (except monoclonal antibodies) or daily chemotherapies,will provide time to achieve all the required tests and examinations. The randomization program will allocate the following treatments with a 2:1 ratio in favor of Arm A of the considered substudy: Substudy 1 : targeted therapies versus standard maintenance chemotherapy - Arm A1 / targeted arm: targeted maintenance from a list of 8 targeted drugs guided by the genomic analysis, or - Arm B1 / chemotherapy arm : maintenance chemotherapy (or no antineoplastic treatment in case of toxicity at the time of randomization) Substudy 2 : immunotherapy versus standard maintenance chemotherapy - Arm A2 / immunotherapy maintenance arm: MEDI4736 or - Arm B2 / chemotherapy arm: chemotherapy continued as a maintenance chemotherapy (or no antineoplastic treatment in case of toxicity)


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1460
Est. completion date December 2024
Est. primary completion date December 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Screening phase: Inclusion Criteria: - Women (or men) with histologically proven breast cancer - Metastatic relapse or progression or stage IV at diagnosis - No Her2 over-expression - Patients with metastases that can be biopsied, except bone metastases - Patients who are eligible for a first or a second line of chemotherapy in metastatic setting (left to the discretion of investigators), or who are currently treated with a first or second line of chemotherapy with a maximum of 2 cycles at the time of biopsy. Screening of patients currently treated with a second line chemotherapy should have a stable disease - For patients with ER+ disease, relapse or progression occurred during endocrine therapy, whatever the line, or less than 12 months after the end of endocrine therapy in adjuvant context - Age =18 years - WHO Performance Status 0/1 - Presence of measurable target lesion according to RECIST criteria v1.1 Exclusion criteria: - Spinal cord compression and/or symptomatic or progressive brain metastases - Bone metastases when this is the only site of biopsiable disease - Patients with all target lesions in a previously irradiated region, except if clear progression has been observed prior to study in at least one of them - Patient who received more than 2 lines of chemotherapy at the time of the biopsy - Tumor progression observed with the current line of treatment when under 2nd line - Patients who already had a genomic profile (both CGH and NGS analysis) in which no SAFIR02 targetable alterations have been identified - Abnormal coagulation contraindicating biopsy - Inability to swallow - Major problem with intestinal absorption Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG Any factors increasing the risk of QTc prolongation or arrhythmic events Experience of any of the following in the preceding 12 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, past or current uncontrolled angina pectoris, congestive heart failure NYHA Grade =2, torsades de pointes, current uncontrolled hypertension, cardiomyopathy Past medical history of interstitial lung disease, drug-induced interstitial disease, radiation pneumonitis which requires steroid treatment or any evidence of clinically interstitial lung disease Previous or current malignancies of other histologies within the last 5 years, Evidence of severe or uncontrolled systemic disease (active bleeding diatheses, or active Hepatitis B, C and HIV) - diagnosis of acne rosacea, severe psoriasis and severe atopic eczema - Prior exposure to anthracyclines or mitoxantrone with cumulative exposure in excess of 360 mg/m² for doxorubicin, 720 mg/m² for epirubicin, or 72 mg/m² for mitoxantrone - Previous treatment with the same agent or in the same class as one of those used in the SAFIR02 trial (patients who received this previous targeted agent without the target prescreening are eligible but may not be eligible for randomisation in substudy 1 if the treatment allocated by the MTB is in the same class) History of retinal degenerative disease, eye injury or corneal surgery in the previous 3 months, past history of central serous retinopathy or retinal vein occlusion, intraocular pressure >21 mmHg, or uncontrolled glaucoma. - History of hemorrhagic or thrombotic stroke, TIA or other CNS bleeds - Renal disease including glomerulonephritis, nephritic syndrome, Fanconi syndrome, renal tubular acidosis - Patients using drugs that are known potent inhibitors or potent inducers or substrates of cytochrome P450 Randomized phase: Substudy 1: Inclusion Criteria: - Patients who received 6 to 8 cycles of chemotherapy, or having received at least 4 cycles of chemotherapy definitively stopped for toxicity reasons, and who are presenting a SD or PR at randomization - presenting at least one genomic alteration from the predefined list - Age =25 years for patients planned to receive AZD4547 - 28-day wash-out period from chemo prior to randomization and grade =1 residual toxicities Exclusion Criteria: - More than 2 previous lines of chemotherapy for metastatic disease before randomization - Life expectancy <3 months - Disease progression occuring at any time during chemotherapy and before randomization or toxicity that led to the discontinuation of the last chemotherapy before 4 full cycles have been delivered - Less than 28 days from radiotherapy, less than 2 weeks from palliative radiation - Patients previously treated with a targeted agent in the same class as the agent to be given to the patient in substudy 1 - Toxicities of grade =2 from any previous anti-cancer therapy - Altered haematopoietic or organ function - Mean resting corrected QT interval (QTc) >480 msec (or QTcF >450 msec) obtained from 3 consecutive ECGs - Left ventricular ejection fraction (LVEF) <55% (MUGA scan or Echocardiogram) - Altered ophthalmic conditions confirmed by an ophthalmology specialist for patients likely to be treated with AZD4547 orAZD8931 or Selumetinib - Patients using non-substitutable drugs, that are known to prolong QT interval or induce Torsades de Pointes, when they are supposed to be treated with vandetanib, AZD5363 or AZD8931 Substudy 2: Inclusion Criteria: - Patients who received 6 to 8 cycles of chemotherapy, or having received at least 4 cycles of chemotherapy definitively stopped for toxicity reasons, and who are presenting a SD or a RP at randomization - Patients not eligible to substudy 1 - wash-out period of at least 15 days for weekly (except monoclonal antibodies) or daily chemotherapies or 28 days for other chemotherapies from last chemotherapy administration prior to randomization and grade =1 residual toxicities Exclusion Criteria: - More than 2 previous lines of chemotherapy for metastatic disease before randomization - Life expectancy <3 months - Disease progression occuring at any time during chemotherapy and before randomization or toxicity that led to the discontinuation of the last chemotherapy before 4 full cycles have been delivered - Any previous treatment with a PD1 or PD-L1 inhibitor, including MEDI4736 - Toxicities of grade =2 from any previous anti-cancer therapy - Altered haematopoietic or organ function - Mean resting QT interval corrected for heart rate (QTc) =470 ms calculated from 3 consecutive ECGs using Bazett's Correction - Current or prior use of immunosuppressive medication within 28 days before the first dose of MEDI4736, with the exceptions of intranasal and inhaled corticosteroids or systemic corticosteroids at physiological doses, which are not to exceed 10 mg/day of prednisone, or an equivalent corticosteroid - Active or prior documented autoimmune disease within the past 2 years NOTE: Subjects with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded - History of primary immunodeficiency

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AZD2014
Target: m-TOR
AZD4547
Target: EGFR
AZD5363
Target: AKT
AZD8931
Target: HER2, EGFR
Selumetinib
Target: MEK
Vandetanib
Target: VEGF, EGFR
Bicalutamide
target: Androgen receptor
Olaparib
Target: PARP
Anthracyclines
DNA intercalation
Taxanes
Target: mitotic tubulin and microtubules
cyclophosphamide
Alkylating agents
DNA intercalators
DNA intercalators
Methotrexate
DNA intercalators
vinca alkaloids
Target: mitotic tubulin and microtubules
Platinum based chemotherapies
Platinum based chemotherapies
Bevacizumab
Target: VEGF
Mitomycin C
Alkylating agents
Eribulin
Microtubule modulator
MEDI4736
Target: PD-L1

Locations

Country Name City State
France Institut de Cancérologie de l'Ouest/Paul Papin Angers
France Institut Sainte-Catherine Avignon
France Institut Bergonié Bordeaux
France Polyclinique Bordeaux Nord Aquitaine Bordeaux
France Centre François Baclesse Caen
France Centre Jean Perrin Clermont-Ferrand
France Centre Georges François Leclerc Dijon
France Chd Vendee La Roche-sur-Yon
France Centre Oscar Lambret Lille
France Chu Dupuytren Limoges
France Centre Hospitalier Lyon Sud Lyon
France Centre Léon Bérard Lyon
France Institut Paoli Calmettes Marseille
France Institut Régional du Cancer Montpellier Val d'Aurelle Montpellier
France Centre Alexis Vautrin Nancy
France Institut de Cancérologie de l'Ouest/ René Gauducheau Nantes
France Centre Antoine Lacassagne Nice
France Institut Curie Paris
France Centre Eugène Marquis Rennes
France Centre Henri Becquerel Rouen
France Institut Curie Saint-Cloud
France Hopitaux Universitaire de Strasbourg - Hopital Civil Strasbourg
France Hopitaux Du Leman Thonon-les-Bains
France Institut Claudius Regaud Toulouse
France Gustave Roussy Villejuif

Sponsors (3)

Lead Sponsor Collaborator
UNICANCER AstraZeneca, Fondation ARC

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival in the targeted drug arm compared to standard maintenance therapy arm To evaluate whether treatment with targeted agents guided by high throughput molecular analysis (CGH array, next generation sequencing) improves progression-free survival as compared to standard maintenance therapy in patients with metastatic Breast Cancer from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
Secondary progression-free survival in patients treated with anti-PDL1 antibody (MEDI4736) compared to standard maintenance therapy arm To evaluate whether treatment with MEDI4736 improves progression-free survival as compared to standard maintenance therapy in patients with metastatic Breast Cancer from randomization to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
Secondary overall survival in each substudy To evaluate whether treatment with targeted agents guided by high throughput molecular analysis (CGH array, next generation sequencing) or MEDI4736 improves overall survival as compared to standard maintenance therapy in patients with metastatic Breast Cancer from randomization to death (any cause), up to 16 months
Secondary overall response rates and changes in tumor size in each substudy tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria tumor response is assessed every 21 days from treatment initiation until first progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
Secondary evaluate safety, in each substudy Toxicities are graded according to the CTCAE V4 toxicities will be assessed during the whole treatment period (4 months expected in average) followed by a 1-year post-treatment follow-up period, and reported during the visits scheduled by the study flow chart
Secondary efficacy (response rate, change in tumor size, progression-free survival, overall survival) and safety of each individual targeted agent (substudy 1) tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria tumor response is assessed every 21 days from treatment initiation until first progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
Secondary correlate molecular characteristics in patients with the efficacy endpoints (response rate, progression-free and overall survival) in each substudy tumor response is defined as a complete or partial response, upon RECIST v1.1 criteria from randomization or treatment initiation to disease progression or death from any cause, whichever comes first, up to 16 months (estimated treatment duration average: 4 months)
See also
  Status Clinical Trial Phase
Withdrawn NCT04872608 - A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer Phase 1
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Completed NCT02506556 - Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer Phase 2
Recruiting NCT05534438 - A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer Phase 2
Recruiting NCT03368729 - Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer Phase 1/Phase 2
Completed NCT04103853 - Safety, Tolerability, and Pharmacokinetics of Proxalutamide Therapy in Women With Metastatic Breast Cancer Phase 1
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Active, not recruiting NCT03147287 - Palbociclib After CDK and Endocrine Therapy (PACE) Phase 2
Not yet recruiting NCT06062498 - Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer Phase 2
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Active, not recruiting NCT04432454 - Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation Phase 2
Recruiting NCT03323346 - Phase II Trial of Disulfiram With Copper in Metastatic Breast Cancer Phase 2
Recruiting NCT05744375 - Trastuzumab Deruxtecan in First-line HER2-positive Locally Advanced/MBC Patients Resistant to Trastuzumab+Pertuzumab Phase 2
Completed NCT02924883 - A Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Participants With Human Epidermal Growth Factor-2 (HER2) Positive Locally Advanced or Metastatic Breast Cancer (BC) Who Received Prior Trastuzumab and Taxane Based Therapy Phase 2
Completed NCT01881230 - Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) Phase 2/Phase 3
Completed NCT01942135 - Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3) Phase 3
Active, not recruiting NCT04448886 - Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC Phase 2
Completed NCT01401959 - Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy Phase 2
Terminated NCT04720664 - Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer Phase 2